Porton Fine Chemicals was established in 2005 and is a leading Chinese contract development and manufacturing organization (CDMO) in the pharmaceutical industry. In 2014, the company went public on the Shenzhen Stock Exchange (stock code: 300363). Porton Fine Chemicals primarily serves global pharmaceutical companies and new drug development institutions, offering customized research and production services for chemical drugs, biological drugs, and formulations from early clinical research to commercialization.

As a national high-tech enterprise, we strive to provide exceptional end-to-end CDMO services for our global clients. With our research, production, and operational facilities located in Chongqing, Chengdu, Shanghai, Jiangxi, Suzhou, Hong Kong, the United States, Switzerland, and the United Kingdom, we have a dedicated team of over 3,000 employees worldwide